Bioactivation of nitroglycerin and vasomotor response to nitric oxide are impaired in cirrhotic rat livers

被引:35
作者
Dudenhoefer, AA
Loureiro-Silva, MR
Cadelina, GW
Gupta, T
Groszmann, RJ
机构
[1] VA Med Ctr, Hepat Hemodynam Lab, West Haven, CT USA
[2] Yale Univ, Sch Med, New Haven, CT USA
基金
巴西圣保罗研究基金会;
关键词
D O I
10.1053/jhep.2002.34739
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nitroglycerin (NTG), a nitric oxide (NO) donor, has been shown to reduce portal pressure in cirrhotic patients. Using the in situ perfusion of normal and cirrhotic rat livers, we compared the vascular relaxation induced by either NTG or the spontaneous nitric oxide donor S-nitroso-N-acetylpenicillamine (SNAP). Normal and cirrhotic livers were perfused (40 mL/min, 37degreesC) with Krebs' solution in a recirculating system. After preconstriction with methoxamine (10(-4) mol/L), a dose-response study was performed using 6 cumulative doses of NTG or SNAP (10(-7) to 3 x 10(-5) mol/L). NOX (NO2 + NO3-) production in the perfusate was measured by chemiluminescence. Cirrhotic livers exhibited lower vasorelaxant responses, compared with normal livers, to both NTG (P < .0001) and SNAP (P = .0020). In normal livers, NTG and SNAP induced similar vasorelaxant responses (P = .44). In cirrhotic livers, NTG induced less vasorelaxation than SNAP (P < .0001). In the presence of NTG (P = .0045), but not SNAP (P = .99), NOX production in experiments with cirrhotic livers was lower than in experiments with normal livers. In conclusion, in cirrhotic rat livers, the vasorelaxant response to NTG is impaired owing to both a decreased metabolism of this NO donor and an inability of the hepatic vasculature to respond to NO.
引用
收藏
页码:381 / 385
页数:5
相关论文
共 34 条
[1]   MEASUREMENT OF NITRIC-OXIDE IN BIOLOGICAL MODELS [J].
ARCHER, S .
FASEB JOURNAL, 1993, 7 (02) :349-360
[2]   REDUCTION OF THE INCREASED PORTAL VASCULAR-RESISTANCE OF THE ISOLATED PERFUSED CIRRHOTIC RAT-LIVER BY VASODILATORS [J].
BHATHAL, PS ;
GROSSMAN, HJ .
JOURNAL OF HEPATOLOGY, 1985, 1 (04) :325-337
[3]  
BRIEN JF, 1988, J PHARMACOL EXP THER, V244, P322
[4]  
CHUNG SJ, 1990, J PHARMACOL EXP THER, V253, P614
[5]   HUMAN ENDOTHELIAL-CELLS BIOACTIVATE ORGANIC NITRATES TO NITRIC-OXIDE - IMPLICATIONS FOR THE REINFORCEMENT OF ENDOTHELIAL DEFENSE-MECHANISMS [J].
FEELISCH, M ;
BRANDS, F ;
KELM, M .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1995, 25 (10) :737-745
[6]   The use of nitric oxide donors in pharmacological studies [J].
Feelisch, M .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) :113-122
[7]   PORTAL PRESSURE, PRESENCE OF GASTROESOPHAGEAL VARICES AND VARICEAL BLEEDING [J].
GARCIATSAO, G ;
GROSZMANN, RJ ;
FISHER, RL ;
CONN, HO ;
ATTERBURY, CE ;
GLICKMAN, M .
HEPATOLOGY, 1985, 5 (03) :419-424
[8]   THE ISOLATED PERFUSED-RAT-LIVER - CONCEPTUAL AND PRACTICAL CONSIDERATIONS [J].
GORES, GJ ;
KOST, LJ ;
LARUSSO, NF .
HEPATOLOGY, 1986, 6 (03) :511-517
[9]  
GROSSMAN HJ, 1984, METHOD FIND EXP CLIN, V6, P33
[10]   NITROGLYCERIN IMPROVES THE HEMODYNAMIC-RESPONSE TO VASOPRESSIN IN PORTAL-HYPERTENSION [J].
GROSZMANN, RJ ;
KRAVETZ, D ;
BOSCH, J ;
GLICKMAN, M ;
BRUIX, J ;
BREDFELDT, J ;
CONN, HO ;
RODES, J ;
STORER, EH .
HEPATOLOGY, 1982, 2 (06) :757-762